drugset / Trial / NCT03896295
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)
Timeline
- Start
- 2019-08-06
- Primary completion
- 2020-12-09
- Completion
- 2020-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nipocalimab | Monoclonal antibody | — | Intravenous |